Amgen (AMGN) Posts Solid Q1, All Eyes Now on Repatha CV Outcomes Trial - BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Amgen (AMGN) PT Raised to $186 at Leerink Partners
April 29, 2016 6:58 AM EDTLeerink Partners analyst Geoffrey Porges raised his price target on Amgen (NASDAQ: AMGN) to $186.00 (from $179.00) following solid Q1 results but stopped short of upgrading the stock and maintained an Market Perform rating.
Porges commented, "Revenue of $5.527bn handily beat consensus by 5%, although it fell short of our estimate of $5.66bn by 2% (Exhibit 1). The main drivers of the revenue... More
Amgen (AMGN) Tops Q1 EPS by 30c, Raises FY Guidance
April 28, 2016 4:03 PM EDTAmgen (NASDAQ: AMGN) reported Q1 EPS of $2.90, $0.30 better than the analyst estimate of $2.60. Revenue for the quarter came in at $5.53 billion versus the consensus estimate of $5.32 billion.
GUIDANCE:
Amgen sees FY2016 EPS of $10.85-$11.20, versus prior guidance of $10.60-$11.00 and... More
